Evercore ISI analyst Vijay Kumar added Caris Life Sciences (CAI) to the firm’s “Tactical Outperform” list. The stock has pulled back 20% since Q2 while “peers have hung in well,” notes the analyst, who expects a “solid” revenue beat when the company reports Q3 results. Evercore has an Outperform rating and $40 price target on Caris shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences publishes study in Oncotarget on MI Cancer Seek
- Caris Life Sciences publishes results of antibody-drug study in breast cancer
- Caris Life Sciences price target raised to $45 from $38 at BTIG
- Caris Life Sciences price target raised to $42 from $34 at Citi
- Caris Life Sciences Reports Strong Q2 2025 Results